MAPT and Alzheimer disease: We found that total tau and phosphorylated tau levels distinguished the AD group from the control group best, whereas the best biomarker to distinguish the AD group from the non-AD group was the t-tau/Aβ42 ratio; decreased Aβ42 with increased tau seems specific for AD dementia in degenerative disorders.